問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Radiation Therapy

Division of General Internal Medicine

Division of General Surgery

Division of Urology

Digestive System Department

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-09-19

蘇柏榮Su, Po-Jung
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -3 個月

  • pjsu@cgmh.org.tw

  • migelee@gmail.com

Recruiting Trial

107Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇柏榮

List

170Cases

2026-05-01 - 2030-05-31

Phase III

Not yet recruiting
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

  • Condition/Disease

    Advanced Clear Cell Renal Cell Carcinoma

  • Test Drug

    AB521 (Casdatifan) 25mg/ Placebo 30 tablets/bottle

Participate Sites
4Sites

Not yet recruiting1Sites

2026-11-01 - 2030-10-30

Phase II/III

Not yet recruiting
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)

  • Condition/Disease

    Locally advanced or metastatic urothelial carcinoma

  • Test Drug

    Datopotamab Deruxtecan

Participate Sites
3Sites

Not yet recruiting3Sites

2026-05-01 - 2030-12-31

Phase III

Not yet recruiting
A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas

  • Condition/Disease

    Extrapulmonary Neuroendocrine Cancer (epNEC)

  • Test Drug

    注射用凍晶粉末 注射用懸液劑 注射用懸液劑

Participate Sites
3Sites

Recruiting2Sites

2026-06-01 - 2032-12-31

Phase III

Not yet recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma

  • Condition/Disease

    High-risk Muscle Invasive Urothelial Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑

Participate Sites
6Sites

Not yet recruiting1Sites

2024-10-01 - 2029-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-12-01 - 2031-05-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2024-12-17 - 2030-08-23

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting
Multicenter, Phase III, Randomized, Placebo-controlled, Double-blind Study of Combination Therapy with D07001 Softgel Capsules and Capecitabine Versus Placebo and Capecitabine in Participants with Advanced Biliary Tract Cancer after Treatment Failure with Gemcitabine, Platinum, and FOLFOX or Irinotecan Regimens

  • Condition/Disease

    Biliary Tract Cancer (BTC)

  • Test Drug

    CAPECITABINE D07001-Softgel Capsules Placebo 艾結達膜衣錠 500 毫克 克癌特膜衣錠150毫克 克癌特膜衣錠500毫克 截瘤達錠５００毫克

Participate Sites
9Sites

Not yet recruiting9Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2025-05-26 - 2031-01-28

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB